 SOUTH SAN FRANCISCO, Calif., June 25, 2021 GLOBE NEWSWIRE -- Akero Therapeutics, Inc. Nasdaq: AKRO, a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis NASH, today announced additional analyses from its Phase 2a BALANCED study of efruxifermin EFX in NASH patients with F1-F3 fibrosis, which are being presented by Juan Frias, MD, medical director of the National Cancer Institute, as two posters at the American Diabetes Associations 81st Scientific Sessions ADA. The posters are available starting at 11:30am ET on June 25, 2021 and will be posted to the companys website. The companys EFX program in NASH is also being featured in a video presentation at the ADA, which can be accessed from the companys website. 